Rajarsi Mandal

Dr. Rajarsi Mandal


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MGMeytal Guller
Meytal Guller
MHMatthew Herberg
Matthew Herberg
NANeha Amin
Neha Amin
HAHosam Hani Alkhatib
Hosam Hani Alkhatib
CMChristopher A Maroun
Christopher A Maroun
RMRajarsi Mandal
Rajarsi Mandal
The association between pretreatment nutritional status and immunotherapy response in patients with advanced head and neck cancer is unclear. We retrospectively analyzed a cohort of 99 patients who underwent treatment with anti-PD-1 or anti-CTLA-4 antibodies (or both) for stage IV HNSCC between 2014 and 2020 at the Johns Hopkins Hospital. Patient demographics and clinical characteristics were retrieved from electronic medical records. Baseline prognostic nutritional index (PNI) scores and pretreatment body mass index (BMI) trends were calculated. Associations between PNI and BMI were correlated with overall survival (OS), progression-free survival (PFS), and immunotherapy response. In univariate analysis, there was a significant correlation between OS and PFS with baseline PNI (OS: HR: 0.464; 95% CI: 0.265–0.814; PFS: p = 0.007 and HR: 0.525; 95% CI: 0.341–0.808; p = 0.003). Poor OS was also associated with a greater decrease in pretreatment BMI trend (HR: 0.42; 95% CI: 0.229–0.77; p = 0.005). In multivariate analysis, baseline PNI but not BMI trend was significantly associated with OS and PFS (OS: log (HR) = −0.79, CI: −1.6, −0.03, p = 0.041; PFS: log (HR) = −0.78, CI: −1.4, −0.18, p = 0.011). In conclusion, poor pretreatment nutritional status is associated with negative post-immunotherapy outcomes.

7 April 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
YXYimin Xu
Yimin Xu
GZGangcai Zhu
Gangcai Zhu
CMChristopher A. Maroun
Christopher A. Maroun
IWIrene X. Y. Wu
Irene X. Y. Wu
DHDonghai Huang
Donghai Huang
XZXin Zhang
Xin Zhang
Background: Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors have provided clinical benefit to head and neck squamous cell carcinoma (HNSCC) patients in recent clinical trials. However, it remains unclear as to whether human papillomavirus (HPV) status is associated with improved clinical outcome of anti-PD-1 or anti-PD-L1 immunotherapy in HNSCC.Methods: PubMed, EMBASE, Cochrane Library, and Web of Science were systematically searched up to February 28, 2021. Published clinical trials of HNSCC patients treated with only PD-1 or PD-L1 inhibitors were selected. The primary or secondary outcome of these studies included objective response rate (ORR) stratified by HPV status. The pooled odds ratio (OR) and hazard ratio (HR) were estimated using a fixed-effect model.Results: A total of seven eligible studies comprising 814 patients were included. The ORR of HPV positive HNSCC patients was significantly higher than that of HPV negative HNSCC patients (OR = 1.77; 95%CI = 1.14-2.74; P = 0.01), and this favorable effect occurred in pooled anti-PD-L1 trials (OR = 2.66; 95%CI = 1.16-6.11; P = 0.02). In comparison, the pooled OR was 1.51 in anti-PD-1 trials (95%CI = 0.90-2.54; P = 0.12). Survival analysis indicated that HPV positive HNSCC patients had a lower risk of overall death as compared to HPV negative HNSCC patients (HR = 0.77; 95%CI = 0.60–0.99; P = 0.04).Conclusions: HPV positive HNSCC patients display improved outcomes with PD-1/PD-L1 axis blockade as compared to HPV negative HNSCC patients. These improved outcomes are likely driven to a greater extent by anti-PD-L1 inhibitors. However, randomized controlled trials with greater numbers of patients are needed for validation of these early findings.

26 November 2021 in Head & Neck
Verified
Journal Article
Closed access
PDF file
NANeha Amin
Neha Amin
CMChristopher A. Maroun
Christopher A. Maroun
MAMargueritta El Asmar
Margueritta El Asmar
HAHosam Hani Alkhatib
Hosam Hani Alkhatib
MGMeytal Guller
Meytal Guller
RMRajarsi Mandal
Rajarsi Mandal

11 September 2019 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
CMChristopher A. Maroun
Christopher A. Maroun
SPSo‐Jin Park
So‐Jin Park
MAMarie Line El Asmar
Marie Line El Asmar
GZGangcai Zhu
Gangcai Zhu
CGChristine G. Gourin
Christine G. Gourin
RMRajarsi Mandal
Rajarsi Mandal

18 November 2021 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
GZGangcai Zhu
Gangcai Zhu
NANeha Amin
Neha Amin
MHMatthew E. Herberg
Matthew E. Herberg
CMChristopher A. Maroun
Christopher A. Maroun
HWHao Wang
Hao Wang
RMRajarsi Mandal
Rajarsi Mandal
In the US, approximately 35 000 new cases of human papillomavirus (HPV)–associated cancers are diagnosed each year, including cervical, head and neck, anal, vulvovaginal, and penile cancers.1 The incidence of HPV-associated head and neck cancers has been steadily increasing in North America and Europe2,3 owing primarily to oropharyngeal squamous cell cancers, 75% of which are now HPV positive in the US.4 Human papillomavirus status is a prognostic biomarker for oropharyngeal squamous cell carcinoma (OPSCC),5 and National Comprehensive Cancer Network guidelines6 recommend the use of HPV status to determine American Joint Committee on Cancer staging because HPV-positive OPSCC is now considered a distinct entity from HPV-negative OPSCC.6,7 Whether HPV is a survival-favorable factor in cancer sites outside the oropharynx remains controversial; testing of nonoropharyngeal head and neck squamous cell carcinoma (non-OP HNSCC) tumors for HPV tumor status is currently not recommended by the National Comprehensive Cancer Network,6 College of American Pathologists,8 or American Society of Clinical Oncology.9

16 April 2020 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
CMChristopher A. Maroun
Christopher A. Maroun
GZGangcai Zhu
Gangcai Zhu
CFCarole Fakhry
Carole Fakhry
CGChristine G. Gourin
Christine G. Gourin
TSTanguy Y. Seiwert
Tanguy Y. Seiwert
RMRajarsi Mandal
Rajarsi Mandal